

**Merrion Pharmaceuticals Plc to Present at AACR-NCI-EORTC  
International Molecular Targets & Cancer Therapeutics Conference in  
Boston, MA**

Dublin, Ireland 21<sup>st</sup> October 2009

Merrion Pharmaceuticals Plc, an international specialty pharmaceutical company, is to present at 2009 AACR – NCI – EORTC International Molecular Targets and Cancer Therapeutics Conference in Boston next month.

Merrion's company presentation, "Safety Profile of Zoledronic Acid in a Novel Oral Formulation", will be presented on Tuesday 17<sup>th</sup> November 2009 from 12.30pm – 2.30pm in Halls C-D, 2<sup>nd</sup> Floor, Hynes Convention Centre, Boston, MA. This presentation covers results from clinical studies of Orazol™.

Orazol™ is a once weekly tablet form of zoledronic acid, which is currently only available as an intravenous infusion (Zometa® and other trademarks, Novartis). Orazol™ has completed Phase II study in cancer patients, with results presented at the ASCO conference (May 2009) and the ASCO Breast Cancer Conference (October 2009). Zoledronic acid is a very potent and thoroughly investigated bisphosphonate compound, which has been used to treat over 3 million patients worldwide. Orazol™, as a weekly tablet formulation offers many new potential advantages to patients, physicians and healthcare providers.

ENDS

Media enquiries

Young Communications

Wally Young

+353 (0)1 668-0530

+353 (0)8 7247-1520

[youngcom@eircom.net](mailto:youngcom@eircom.net)

**About Merrion:**

Merrion Pharmaceuticals ([www.merrionpharma.com](http://www.merrionpharma.com)) is a publicly listed specialty pharmaceutical company engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection. Merrion was established in 2003 to commercialize various technologies acquired from Elan Corporation, plc. Merrion Pharmaceutical's patented drug delivery technologies increase bioavailability, by improving absorption in the gastrointestinal tract, of drugs that are otherwise poorly absorbed. This can provide substantial benefit in patient convenience and safety, and might also provide enhanced drug efficacy. Merrion utilizes its technology to develop new oral drugs in two ways; it develops its own proprietary drugs using GIPET and partners with other pharmaceutical companies in developing oral GIPET formulations of their products.

**About AACR:**

AACR was founded in 1907 by a group of 11 physicians and scientists interested in research, "to further the investigation and spread the knowledge of cancer." Today, the AACR accelerates progress toward the prevention and cure of cancer by promoting research, education, communication, and collaboration.

The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.